Abstract Accumulating evidence suggests that human cd T cells act as non-classical T cells and contribute to both innate and adaptive immune responses in infections. Vc2 Vd2 T (also termed Vc9 Vd2 T) cells exist only in primates, and in humans represent a dominant circulating cd T-cell subset. Primate Vc2 Vd2 T cells are the only cd T cell subset capable of recognizing microbial phosphoantigen. Since nonhuman primate Vc2 Vd2 T cells resemble their human counterparts, in-depth studies have been undertaken in macaques to understand the biology and function of human Vc2 Vd2 T cells. This article reviews the recent progress for immune biology of Vc2 Vd2 T cells in infections.
Introduction
Accumulating evidence suggests that human cd T cells function as non-classical T cells and contribute to both innate and adaptive immune responses in infections [1] [2] [3] [4] . Vc2 Vd2 T (also termed Vc9 Vd2 T) cells exist only in primates, and in humans represent a major circulating cd T cell subset that normally constitutes up to 65-90% of total peripheral blood cd T cells. Since macaque Vc2 Vd2 T cells resemble their human counterparts, in-depth studies have been undertaken in nonhuman primates to understand biology and function of human Vc2 Vd2 T cells. This article reviews the recent progress for immune responses of Vc2 Vd2 T cells in infections.
Infection-driven adaptive immune responses of phosphoantigen-specific human Vc2 Vd2 T cells
A number of laboratories including ours have demonstrated that Vc2 Vd2 T cells can be activated in vitro by certain low m.w. foreign-and self-nonpeptidic phosphorylated metabolites of isoprenoid biosynthesis [e.g., (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP), isopentenyl pyrophosphate (IPP) and its isomer dimethylallyl pyrophosphate (DMAPP)] [7] [8] [9] [10] [11] commonly referred to as phosphoantigens. Microbial phosphoantigen HMBPP is produced in the 2-C-methyl-Derythritol-4-phosphate (MEP) pathway of isoprenoid biosynthesis of a number of bacteria and protozoa [5] . Infections of humans or nonhuman primates with HMBPP-producing microbes can induce major expansion of Vc2 Vd2 T cells [5] . Typically, Mycobacterium bovis BCG and Mycobacterium tuberculosis both produce HMBPP, and early infections of macaques with these mycobacteria can induce remarkable expansion of Vc2 Vd2 T cells [1] . Surprisingly, BCG re-infection or BCG infection followed by M. tuberculosis challenge can induce rapid recall expansion or adaptive immune responses in macaques [1] . Re-occurrence of clonotypic TCR sequences of Vc2 Vd2 T cells is also evident during rapid recall expansion, suggesting the memory-like responses [1] . Our new studies provide additional in vivo evidence indicating that rapid recall expansion or adaptive immune response of Vc2 Vd2 T cells can also be induced during re-infection of macaques with Listeria monocytogenes capable of producing HMBPP (Ryan et al., 2010 International cd T cell conference). In fact, increases in human cd T cells or Vc2 Vd2 T cells were reported in leprosy granulomatous disease and tuberculous meningitis, respectively (see review [6] ). Examples for infection-driven expansion of human cd T cells also include salmonellosis, brucellosis, legionellosis, tularemia, brucellosis, Legionellosis, malaria, toxoplasmosis, Leishmaniasis and others (see review [6] ). The notion that human Vc2 Vd2 T cells can mount adaptive immune response in infections is also supported by other human studies [5, [7] [8] [9] [10] [11] [12] . However, like CD4? or CD8? T cells, Vc2 Vd2 T cells appear to be depressed in terms of frequency or effector function during chronically active tuberculosis or chronic phase of AIDS virus infections [13, 14] . It is still debatable as to whether such depressed Vc2 Vd2 T cells contribute to the development of active tuberculosis or result from immune dysfunction in chronic tuberculosis.
The extraordinary expansion and recall expansion of Vc2 Vd2 T cells in infections indeed argue against the old simple paradigm that human cd T cells completely function as innate cells. Notably, human cd T cells have been long considered innate cells due to the lack of convincing evidence indicating major clonal expansion and adaptive feature for these cd T cells. Nevertheless, the emerging evidence suggests that human Vc2 Vd2 T cells can have both innate and adaptive immune features in infections.
It is likely that the infections with HMBPP-producing pathogens are the driving forces for adaptive immune response of Vc2 Vd2 T cells. Our new in vivo studies suggest that both HMBPP and infection-driven cytokines are needed for clonal expansion and recall expansion (Ryan et al., unpublished data). This helps to explain at least in part why repeated in vivo treatments of macaques by a phospholigand and IL-2 can induce expansion of Vc2 Vd2 T cells each time, but not necessarily stimulate greater magnitudes of recall expansion each time after the treatment [15] . The finding derived from small phospholigand and IL-2 treatment cannot rule out the possibility that Vc2 Vd2 T cells can contribute to adaptive immune response in infections in that Vc2 Vd2 T cells do not exactly resemble their ab T cell counterpart mounting the typical recall or memory responses when exposed to the simple treatment comprised only of very small phospholigand molecule and IL-2. It is also possible that the initial treatment with phospholigand and IL-2 has already reached the maximum activation/expansion potential of Vc2 Vd2 T cells (up to 80% of T cells are HMBPP/IL2-expanded cd T cells [15, 16] ), and a subsequent treatment will not be able to go beyond the saturated points due to the host selfcontrol mechanism for shutting-down over-expanding T cell clones. A human in vitro study also implicates that HMBPP is different from infection in activation and function of Vc2 Vd2 T cells, as mycobacteria-stimulated Vc2 Vd2 T cells, but not HMBPP-activated Vc2 Vd2 T cells, are able to suppress M. tuberculosis replication [17] .
Molecular mechanism by which Vc2 Vd2 T cells interact with microbial phosphoantigen HMBPP during infections Primate Vc2 Vd2 T cell subset remains the only cd T cells capable of recognizing a microbial phosphoantigen, whereas no defined microbial antigens can be recognized by cd T cells from mice and other species [1] [2] [3] [4] . While the chemistry of phosphoantigens and their ability to activate Vc2 Vd2 T cells have been well described, molecular mechanisms by which HMBPP interacts with cd T cells remain poorly characterized [18] [19] [20] [21] . Most studies done to date have been focused on prenyl pyrophosphates, particularly IPP, but rarely the microbial phosphoantigen HMBPP [22] . Earlier experiments using Vc2 Vd2 T cell activation as readouts demonstrated that IPP does not need to undergo cell-entry or processing and that phosphoantigen activation of Vc2 Vd2 T cells requires cell-cell contact [18, 23] . A putative molecule, but not MHC class I, class II, or CD1, appears to be required to present IPP for immune activation of Vc2 Vd2 T cells [18] . Despite decade-long studies, however, there has been no direct evidence indicating that human or macaque Vc2 Vd2 TCR (instead of human macaque hybrids) can directly bind to HMBPP or HMBPP complex [24, 25] .
We presumed that the development of soluble, tetrameric Vc2 Vd2 TCR would provide a useful approach to explore the molecular mechanism by which Vc2 Vd2 T cells interact with phosphoantigen HMBPP. We therefore took advantage of our decades-long TCR expertise and MHC tetramer technology [26, 27] to develop high-affinity-binding soluble Vc2 Vd2 TCR tetramer [28] . We demonstrated that soluble Vc2 Vd2 TCR tetramer, once labeled with fluorescence, makes it possible to visualize APC presentation of phosphoantigen HMBPP to Vc2 Vd2 TCR [28] . We show that exogenous HMBPP is associated with APC membrane in an appreciable affinity, and that the membrane-associated HMBPP is readily recognized by the Vc2 Vd2 TCR tetramer ( Fig. 1 ) [28] . In fact, the Vc2 Vd2 TCR tetramer stably binds HMBPP presented on membrane by various APC cell lines from humans and nonhuman primates but not those from mouse, rat or pig [28] . This finding suggests that Vc2 Vd2 TCR is one of the important elements dictating the specific recognition of microbial HMBPP by Vc2 Vd2 T cells [28] . The Vc2 Vd2 TCR tetramer also binds the membrane-associated HMBPP on primary monocytes, B cells and some T cells, suggesting that various host immune cells can present HMBPP for activation of Vc2 Vd2 T cells during infections with HMBPP-producing pathogens [28] . Consistently, endogenous phosphoantigen produced in mycobacterium-infected DC is transported and presented on membrane, and stably bound to the Vc2 Vd2 TCR tetramer. This is particularly significant for host responses to infections with HMBPPproducing intracellular pathogens, as the infected APC, such as DC or macrophages, can rapidly present HMBPP to Vc2 Vd2 TCR for early activation and expansion of Vc2 Vd2 T cells. Interestingly, the capability of APC to present HMBPP for recognition by Vc2 Vd2 TCR is diminished after protease treatment of APC. Thus, our studies elucidate that an affinity HMBPP-APC association confers binding to Vc2 Vd2 TCR, and that the putative APC membrane molecule presenting HMBPP appears to be a protein or protein-associated component existing in primate APC or T cells but not rodent APC [28] . Thus, the Vc2 Vd2 TCR tetramer-based studies enhance our understanding of molecular aspects for the interaction between Vc2 Vd2 T cells and APC presenting microbial phosphoantigen HMBPP in infections.
Vc2 Vd2 TCR appears to play a fundamental role in recognition of HMBPP and subsequent clonal activation/expansion of Vc2 Vd2 T cells during infections Since Vc2 Vd2 TCR dictates the specific interaction with microbial phosphoantigen HMBPP, it would be interesting to see the HMBPP-engaged TCR molecule events driving sequential activation and expansion of Vc2 Vd2 T cells in early infections. We presume that molecular imaging of HMBPP-triggered TCR response would be a best approach to elucidate TCR molecule responses. We have innovatively combined near-field optical microscopy (NSOM) and fluorescent quantum dot (QD) nanotechnology (NSOM/QD), and developed a best-opticalresolution nanoscale molecular imaging (\50 nm) system for visualizing molecule events in immune cells. Such a best-optical-resolution molecular imaging system allows us to show that non-stimulating Vc2 Vd2 TCR molecules in resting cd T cells are distributed individually from each other on the cell surface, with mean sizes of \50-70 nm (Fig. 2 ) [29] . However, HMBPP pulsation of APC for engaging Vc2 Vd2 TCR rapidly induces formation of *120-300 nm TCR nanoclusters [29] . Such TCR molecule events coincide with the translocation of PKCh to the membrane for signal transduction and activation (data not shown)
. Surprisingly, such Vc2 Vd2 TCR nanoclusters can be sustained on the membrane during an in vivo clonal expansion of Vc2 Vd2 T cells after HMBPP/IL-2 treatment and mycobacterial infection. The TCR nanoclusters can array to form nanodomains or microdomains on the membrane of clonally-expanded Vc2 Vd2 T cells (Fig. 2 ) [29] . Interestingly, expanded Vc2 Vd2 T cells bearing TCR nanoclusters or nanodomains were able to re-recognize phosphoantigen and to exert better effector function [29] . In contrast, non-specific stimulants cannot induce Vc2 Vd2 TCR nanoclustering or nanodomain formation. These nanoscale novel findings suggest that Vc2 Vd2 TCR plays a fundamental role in recognition of HMBPP and subsequent clonal activation and expansion (4) is extracted from the cross section part (dashed arrow) in (3) that is enlarged from the boxed area in (2) . (5) is the NSOM fluorescence image of another activated/expanded Vc2 Vd2 T cell collected on day 4
of Vc2 Vd2 T cells during infections with HMBPP-producing pathogens.
A critical role of cytokines in adaptive immune responses of Vc2 Vd2 T cells in infections
Some cytokines produced in infections may contribute to the development of adaptive immune responses of Vc2 Vd2 T cells during infections with HMBPP-producing pathogens. This scenario is supported by the studies from us [2] and others [30] . We found that M. tuberculosis and BCG infections of macaques induced major expansion of Vc2 Vd2 T cells and coincident expression of variant IL-4 (VIL-4) mRNA encoding a protein comprised of N-terminal 97 amino acids (a.a.) identical to IL-4, and unique C-terminal 96 a.a. including a signaling-related proline-rich motif. We then expressed and purified VIL-4 to test the possibility that this variant cytokine can contribute to major expansion of Vc2 Vd2 T cells. The purified VIL-4 induces apparent expansion of phosphoantigen HMBPP-specific Vc2 Vd2 T cells in dose-and time-dependent manners [2] . The unique C-terminal 96 a.a. bearing the proline-rich motif (PPPCPP) of VIL-4 appears to confer the ability to expand Vc2 Vd2 T cells, since simultaneously produced IL-4 has only a subtle effect on these cd T cells. Moreover, VIL-4 seems to utilize IL-4 receptor a for signaling and activation, as the VIL-4-induced expansion of Vc2 Vd2 T cells can be blocked by anti-IL-4R a mAb but not anti-IL-4 mAb [2] . Surprisingly, VIL-4-expanded Vc2 Vd2 T cells after HMBPP stimulation appear to be heterologous effector cells capable of producing IL-4, IFN-c and TNF-a [2] . Thus, mycobacterial infections of macaques induced variant mRNA encoding VIL-4 that functions as growth factor promoting expansion of HMBPP-specific Vc2 Vd2 T effector cells [2] . We presume that other cytokines may also exert similar effects facilitating major expansion of Vc2 Vd2 T cells during mycobacterial infections. In fact, it has been reported that IL-21 can also stimulate marked expansion of HMBPPspecific Vc2 Vd2 T cells [30] . between monocytes and human cd T cells can drive fast inflammatory cytokine responses and monocyte differentiation to DC, and facilitate development CD4 T helper cells in the presence of additional microbial stimulants [34] . Activated human Vc2 Vd2 T cells appear to function as APC in vitro, presenting peptide antigens to CD4? and CD8? T cells [35, 36] . Vc2 Vd2 T cells have also been shown to improve B cells' ability to produce antibodies in vitro [32] . Further studies are needed to prove the tentative concept that Vc2 Vd2 T effector cells may potentially enhance Ag-specific Ab response and ab CD4? or CD8? T cell responses in infections.
Vc2 Vd2 T effector cells may function as immune regulators influencing other immune cells and their responses in infections
Activated Vc2 Vd2 T cells produce Th1 cytokines and many other cytokines, and therefore may influence other effector cells in host responses to infections. To assess this possibility, we sought to determine whether Vc2 Vd2 T cells could have direct impact on other T cell populations in vivo during infections or vaccination. Our studies were focused on two aspects: (1) interplay between CD4?CD25?Foxp3? T regulatory cells (Treg) and HMBPP-activated Vc2 Vd2 T effector cells during mycobacterial infection; and (2) Vc2 Vd2 T cell-driven immune regulation of potentially inflammatory IL-22? T cells in tuberculosis.
Foxp3? Treg cells control immune responses to selfand foreign-antigens and play a major role in maintaining the balance between immunity and tolerance [37] [38] [39] . While Treg are beneficial for controlling autoimmunity, allograft rejection, or hypersensitivity, their over-responses in infections may lead to suppression of host anti-microbial immunity [37] . Development of a useful model system may help to identify potential mutual regulatory effects of Treg and other immune cells or elements. Interestingly, recent studies have shown that human recombinant IL-2 administration can lead to an increase in the frequency of circulating CD4?CD25? regulatory T cells in cancer patients [40] [41] [42] [43] . We and others have also shown that IL-2 plus phospholigand treatment can induce remarkable expansion of Vc2 Vd2 T cells in nonhuman primates [15, 16, 44] . We therefore took advantage of the IL-2-based in vivo model systems to assess potential interplay or mutual regulations between Vc2 Vd2 T cells and Treg during early mycobacterial infection in nonhuman primates. Given the possibility that some over-reacting T effector cells may contribute to inflammation or tissue damages in infections, we sought to determine if HMBPP-activated Vc2 Vd2 T cells can regulate those potentially inflammatory cells. In this end, we focused on IL-22? T cells and their interplay with Vc2 Vd2 T cells in infection as IL-22 has been shown to play a role in inflammation or autoimmunity [45] [46] [47] . We first demonstrated in a nonhuman primate model that M. tuberculosis infection results in apparent increases in numbers of T cells capable of producing IL-22 de novo without in vitro Ag stimulation, and drives distribution of these cells more dramatically in lungs than in blood and lymphoid tissues [18, 19] . Consistently, IL-22? T cells are visualized in situ in lung tuberculosis (TB) granulomas by confocal microscopy and immunohistochemistry, indicating that mature IL-22? T cells are present in TB granuloma [18, 19] . Surprisingly, HMBPP activation of Vc2 Vd2 T cells down-regulates the capability of T cells to produce IL-22 de novo in lymphocytes from blood, lung/BAL fluid, spleen and lymph node [18] . Up-regulation of IFNc-producing Vc2 Vd2 T effector cells after HMBPP stimulation coincides with the down-regulated capacity of these T cells to produce IL-22 de novo. Importantly, anti-IFNc neutralizing Ab treatment reversed the HMBPP-mediated down-regulation effect on IL-22? T cells, suggesting that Vc2 Vd2 T cell-driven IFNc-networking function was the mechanism underlying the HMBPP-mediated down-regulation of the capability of T cells to produce IL-22 [18] . These novel findings raise the possibility to ultimately investigate the function of IL-22? T cells and to target Vc2 Vd2 T cells for balancing potentially hyper-activating IL-22? T cells in severe TB.
Vc2 Vd2 T effector cells can readily traffic to lungs and contribute to host resistance to pathogen-induced lung damages during acute pulmonary infection
Our studies have demonstrated that one of the remarkable immune features for HMBPP-specific Vc2 Vd2 T cells is their capability to traffic to lungs and other mucosal surface once they are activated and expanded [16, 48] . However, the possibility that Vc2 Vd2 T effector cells can confer protection against pulmonary infectious diseases has not been tested. Since we reproducibly showed that the HMBPP plus IL-2 treatment can induce prolonged accumulation of Vc2 Vd2 T effector cells in lungs [16, 29, 44, 49] , we investigated whether the expanded Vc2 Vd2 T cells can mediate protection against acutely fatal pneumonic plague in the macaque model of inhalational Yersinia pestis infection. A delayed HMBPP/IL-2 administration after inhalational Yersinia pestis infection overcame acute infection and induced marked expansion of Vc2 Vd2 T cells [49] . Expanded Vc2 Vd2 T cells failed to control extracellular plague bacterial replication/infection, which led to extrathoracic dissemination, septicemia and fatal shock. This appeared to be understandable since an extracellular bacterial infection would usually be controlled by neutralizing antibodies but not T effector cells. Surprisingly, despite the absence of infection control, expansion of Vc2 Vd2 T cells after HMBPP/IL-2 treatment led to the attenuation of inhalation plague lesions in lungs [49] . Consistently, HMBPP-activated Vc2 Vd2 T cells accumulated and localized in pulmonary interstitials surrounding small blood vessels and airway mucosa in the lung tissues with no or mild plague lesions [49] . These infiltrating Vc2 Vd2 T cells produced FGF-7, a homeostatic mediator against tissue damages [50] . In contrast, control macaques treated with glucose plus IL-2 or glucose alone exhibited severe hemorrhages and necrosis in most lung lobes, with no or very few Vc2 Vd2 T cells detectable in lung tissues. The findings are consistent with the paradigm that circulating Vc2 Vd2 T cells can traffic to lungs for homeostatic protection against tissue damages in infection. This finding indeed provides the first in vivo evidence in humans and primates indicating that Vc2 Vd2 T cells can contribute to anti-microbial immunity.
Concluding remarks
In conclusion, much progress has been made over the past years. While infections with phosphoantigen-producing microbes can drive adaptive immune responses of Vc2 Vd2 T cells in humans and nonhuman primates, Vc2 Vd2 TCR appears to be responsible for recognition of phosphoantigen HMBPP presented by APC and subsequent clonal activation/expansion of Vc2 Vd2 T cells during infections. IL-2 and other cytokines produced in infections play a critical role in mounting adaptive immune responses of HMBPP-specific Vc2 Vd2 T cells. Preliminary data suggest that Vc2 Vd2 T effector cells may potentially enhance Ag-specific Ab response and ab CD4? or CD8? T cell responses in infections. In addition, Vc2 Vd2 T effector cells may function as immune regulators antagonizing CD4?CD25?Foxp3? T cells and influencing IL-22? T effector cells in infections. Importantly, Vc2 Vd2 T effector cells can readily traffic to lungs and contribute to host resistance to pathogen-induced lung damage during an acute pulmonary infection.
